A recent study focused on tumour-infiltrating CD8+ T cells that express the HLA-G receptor ILT2 in clear cell renal cell carcinoma (ccRCC), and the results emphasize the potential of therapeutically targeting the HLA-G/ILT2 checkpoint in HLA-G+ tumors (7). The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.